Mesut Erdurmus1, Yuksel Totan. 1. Department of Ophthalmology, Fatih University Medical School, Alparslan Turkes Cad No: 57, 06510 Emek, Ankara, Turkey. merdurmus@yahoo.com
Abstract
OBJECTIVE: To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV). METHODS: This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography. RESULTS: Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months. CONCLUSION: Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
OBJECTIVE: To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV). METHODS: This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography. RESULTS:Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months. CONCLUSION: Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
Authors: Ziad F Bashshur; Ali Bazarbachi; Alexandre Schakal; Zeina A Haddad; Christelle P El Haibi; Baha' N Noureddin Journal: Am J Ophthalmol Date: 2006-07 Impact factor: 5.258
Authors: Halil Ibrahim Onder; Mesut Erdurmus; Yasin Yücel Bucak; Hüseyin Simavli; Murat Oktay; Ahmet Sahap Kukner Journal: Int J Ophthalmol Date: 2014-04-18 Impact factor: 1.779
Authors: Olga Dratviman-Storobinsky; Bat-Chen R Avraham-Lubin; Murat Hasanreisoglu; Nitza Goldenberg-Cohen Journal: Mol Vis Date: 2009-11-13 Impact factor: 2.367